Literature DB >> 22460813

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.

Alison H M Reid1, Gerhardt Attard, Daniel Brewer, Susana Miranda, Ruth Riisnaes, Jeremy Clark, Lucy Hylands, Sue Merson, Roy Vergis, Charles Jameson, Søren Høyer, Karina Dalsgaard Sørenson, Michael Borre, Chris Jones, Johann S de Bono, Colin S Cooper.   

Abstract

There is increasing evidence that multiple chromosomal rearrangements occur in prostate cancer. PTEN loss is considered to be a key event in prostate carcinogenesis but the mechanisms of loss remain to be fully elucidated. We hypothesised that gross rearrangements may exist that cause disruption of the PTEN gene in the absence of genomic deletion. We therefore designed a novel fluorescence in situ hybridisation (FISH) assay with probes overlying regions 3' and 5' of PTEN and a third probe overlying the gene. We aimed to identify both genomic deletions and gross rearrangements of PTEN that would be overlooked by previously reported single-probe FISH assays. We proceeded to evaluate a tissue microarray with radical prostatectomy and trans-urethral resection of the prostate specimens from 187 patients. We identified PTEN genomic loss in 45/150 (30%) radical prostatectomy patients and 16/37 (43%) trans-urethral resection of the prostate patients. Importantly, our assay detected novel chromosomal alterations in the PTEN gene (characterised by splitting of FISH signals) in 13 tumours (6.9% of all prostate cancers; 21% of PTEN-lost cancers). All PTEN-rearranged tumours had genomic loss at the other allele and had no expression of PTEN by immunohistochemistry. PTEN-rearranged tumours were significantly more likely to have an underlying ERG rearrangement. Our assay differentiated loss of the probe overlying PTEN in isolation or in combination with either one of or both the probes overlying the 3' and 5' regions. This gave an indication of the size of genomic loss and we observed considerable inter-tumoural heterogeneity in the extent of genomic loss in PTEN-lost tumours. In summary, gross rearrangements of the PTEN locus occur in prostate cancer and can be detected by a 'break-apart' FISH assay. This observation could explain the absence of PTEN protein expression in a subgroup of tumours previously classified as having heterozygous genomic loss using single-probe traditional FISH assays.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460813     DOI: 10.1038/modpathol.2011.207

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  24 in total

1.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

Review 2.  Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

Authors:  Daniel P Petrylak; E David Crawford
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 3.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

Review 4.  Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.

Authors:  Lucas J Brand; Scott M Dehm
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

5.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Authors:  Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville
Journal:  Mod Pathol       Date:  2015-11-27       Impact factor: 7.842

6.  PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.

Authors:  Tamara L Lotan; Wei Wei; Carlos L Morais; Sarah T Hawley; Ladan Fazli; Antonio Hurtado-Coll; Dean Troyer; Jesse K McKenney; Jeffrey Simko; Peter R Carroll; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Ziding Feng; James D Brooks
Journal:  Eur Urol Focus       Date:  2016-06

Review 7.  The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing.

Authors:  Alexander W Wyatt; Fan Mo; Yuzhuo Wang; Colin C Collins
Journal:  Asian J Androl       Date:  2013-03-18       Impact factor: 3.285

8.  Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

Authors:  Saoirse O Dolly; Andrew J Wagner; Johanna C Bendell; Hedy L Kindler; Lee M Krug; Tanguy Y Seiwert; Marjorie G Zauderer; Martijn P Lolkema; Doris Apt; Ru-Fang Yeh; Jill O Fredrickson; Jill M Spoerke; Hartmut Koeppen; Joseph A Ware; Jennifer O Lauchle; Howard A Burris; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2016-01-19       Impact factor: 12.531

9.  Tumor clone dynamics in lethal prostate cancer.

Authors:  Suzanne Carreira; Alessandro Romanel; Jane Goodall; Emily Grist; Roberta Ferraldeschi; Susana Miranda; Davide Prandi; David Lorente; Jean-Sebastien Frenel; Carmel Pezaro; Aurelius Omlin; Daniel Nava Rodrigues; Penelope Flohr; Nina Tunariu; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2014-09-17       Impact factor: 17.956

10.  First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Authors:  Debashis Sarker; Joo Ern Ang; Richard Baird; Rebecca Kristeleit; Krunal Shah; Victor Moreno; Paul A Clarke; Florence I Raynaud; Gallia Levy; Joseph A Ware; Kathryn Mazina; Ray Lin; Jenny Wu; Jill Fredrickson; Jill M Spoerke; Mark R Lackner; Yibing Yan; Lori S Friedman; Stan B Kaye; Mika K Derynck; Paul Workman; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2014-11-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.